Innovations in care: What you know matters

featured_paragraph

What you know matters when it comes to navigating breast cancer. Whether diagnosed with early-stage or living with metastatic breast cancer, having trusted resources and information provides a roadmap that helps people to find the best way forward for living well beyond their diagnosis.

general_content

This four-part series features discussions that will help individuals further understand their options by providing insight on breakthroughs in treatments, the role of testing, and navigating the cost of cancer care.

The sessions will empower both those diagnosed with early-stage and metastatic breast cancer to make informed decisions about their care and provide strategies to help them advocate for themselves throughout treatment and beyond.

Please email programs@lbbc.org by Tuesday, September 3 to request ASL interpretation

Register now

on_this_page

Session information

Session 1 | Shared decision making and patient choices

Tuesday, September 17 | 12:00- 1:00pm (ET)

Speaker: Don Dizon, MD, FACP, FASCO

In this age of personalized medicine, treatment decision making can be a complex matter. This program will help you understand why there are standards of care in breast cancer treatment, how they impact your treatment decisions, and how to advocate for standard of care if you think you are not receiving the care you deserve.

Session 2 | Innovations in treatment and side effect management

Wednesday, September 25 | 12:00- 1:00pm (ET)

Speaker: Eleonora Teplinsky, MD

Learn about the latest breakthroughs in targeted chemotherapy, how these treatments are administered, the short-term and long-term impacts of chemotherapy and strategies for managing these side effects. We will also explore the evolution beyond chemotherapy, oral therapies that may make treatment more convenient and ways that personalized medicine may impact your treatment plan and provide you with options.

Session 3 | Understanding testing in breast cancer

Tuesday, October 1 | 12:00 – 1:00pm (ET)

Speaker: Reshma Mahtani, DO

This session will explain the role of testing in breast cancer today. Learn about the tests that look for mutations, or changes, in tumors and in the blood and are used to develop a tailored treatment plan for your personalized care.

Session 4 | Practical matters: The financial and time toxicity of breast cancer

Wednesday, October 9 |12:00 - 1:00pm (ET)

Speaker: Pallav Mehta, MD

The term financial toxicity describes both the practical and the emotional impact of the cost of care on individuals and families managing a cancer diagnosis. This session will explain the factors that contribute to financial toxicity, explore their impact, and provide ways to reduce or overcome obstacles. Hear about useful resources to assist with everyday bills, manage costs, and eliminate barriers to quality healthcare.

Back to top

team_callout_card_listing

Speakers

View

Don S. Dizon, MD, FACP, FASCO

Director, The Pelvic Malignancies Program, Lifespan Cancer Institute

Reshma L. Mahtani, DO

Chief of Breast Medical Oncology, Miami Cancer Institute, Baptist Health South Florida

Pallav K. Mehta, MD

Medical Director, Reimagine Care; Assistant Professor of Medicine, MD Anderson Cancer Center at Cooper

Eleonora Teplinsky, MD

Head, Breast and Gynecological Medical Oncology, Valley-Mount Sinai Comprehensive Cancer Care

Back to top

3 Tier Sponsors

Thank you

Back to top

related_resources_article_carousel

Related resources

Can a breast cancer diagnosis be wrong?

07/31/24 | BY: Brian S. Englander

It is unusual but possible for a breast cancer diagnosis to be incorrect. Learn more about the different ways to be certain about a new diagnosis.

| 10 Min. Read

Your pathology report

07/24/24 | BY: Ira Bleiweiss

A pathology report is a profile of the breast cancer’s characteristics, including stage, how quickly it may grow, hormone-receptor status, and HER2 status.

| 18 Min. Read | 5

Oncotype DX

06/05/24 | BY: Laura Huppert

The Oncotype DX Breast Recurrence Score test is a genomic test that can help determine treatment options for hormone-receptor positive, HER2-negative invasive breast cancer.

| 6 Min. Read

MammaPrint

06/05/24 | BY: Laura Huppert

MammaPrint is a genomic test that evaluates the activity of 70 genes to determine risk of breast cancer recurrence and to indicate possible benefit from chemotherapy.

| 4 Min. Read

EndoPredict

06/05/24 | BY: Laura Huppert

EndoPredict is a genomic test used to measure a person’s risk of breast cancer recurring from diagnosis through 15 years.

| 4 Min. Read

Genomic testing

06/05/24 | BY: Laura Huppert

Genomic testing in early-stage breast cancer assesses recurrence risk by analyzing gene activity levels in cancer cells, informing prognosis and treatment response predictions.

| 9 Min. Read | 6

PET Scan

05/03/24 | BY: Sophia R. O'Brien

A PET scan is an imaging test used to detect cancer throughout the body. They are not used to screen for breast cancer, but can help you and your healthcare team make decisions about treatment.

| 8 Min. Read | 3

Tests for metastatic breast cancer

04/17/24 | BY: Debu Tripathy

Many different tests can be involved in a metastatic breast cancer diagnosis. These tests can confirm the extent of the cancer and determine the most effective treatments.

| 11 Min. Read | 5

Biomarker testing

04/15/24 | BY: Pallav K. Mehta

A biomarker is a protein, gene mutation, or other substance that can be tested using a sample of cancer tissue or blood. Biomarker test results can help you and your doctor better understand your cancer and treatment options.

| 22 Min. Read | 1

Breast cancer screening recommendations for transgender people

02/12/24 | BY: Elizabeth Cathcart-Rake, Victoria Seamon

Learn more about breast cancer screening guidelines for transgender people based on age; sex assigned at birth; risk factors; and use of hormone therapy, surgery, or both that may be used in the transitioning process.

| 8 Min. Read